Imaging Contrast

Contrast agents are injected into patients to help enhance images to make it easier for radiologists distinguish specific areas of the body from surrounding tissues. The most commonly used agents are iodinated contrast dye for computed tomography (CT), interventional cath lab angiography,  RF fluoroscopy, and in surgical OR procedures. MRI scans typically use gadolinium-based contrast agents. Ultrasound and echocardiography (cardiac ultrasound) imaging use contrast agents composed of microscopic bubbles to enhance images that otherwise would be suboptimal.

'Critical' oversight of 7 factors increases contrast waste

Since the onset of the iodinated contrast shortage in 2022, countless tactics have been deployed to optimize use of the imaging agent, but many have been overlooked.

Banner ASC in Sun City, Arizona.

Two years after the contrast shortage, how have supply preservation tactics fared?

During an initial three-month intervention period, one health system estimates that its saved nearly 750,000 mL of contrast. Now, experts from the organization are sharing whether those changes stuck after the shortage ended.

'One-stop-shop' CT stroke protocol reduces scan time, contrast dose and radiation exposure

The protocol integrates CT angiography of the head and neck with the tomography perfusion acquisition, eliminating the need for two separate scans.

Using high concentration contrast media reduces patients' pain and discomfort during injections

While most safety considerations associated with contrast injections, like hypersensitivity reactions and extravasation, rarely become reality, pain at the injection site is much more common.

Test bolus of diluted contrast optimizes scan timing during CTA

It also reduces iodine uptake and radiation dose in patients, without sacrificing image quality.

Contrast protocols based on lean body weight save supplies, reduce patient risk

Adjusting contrast dose based on a patient’s lean body weight provides the same image quality as other administration methods, new data show.

The feasibility of reduced contrast flow rates in PE studies

Around one out of every 1,000 people in the U.S. are diagnosed with a pulmonary embolism every year, but even more undergo imaging to rule out clots.  

Thumbnail

Fluorinated contrast agents show 'strong potential' for MRI theranostics

Experts have developed a first-of-its-kind fluorinated contrast agent they believe will provide more detailed MR imaging and aid in the treatment of certain cancers. 

Around the web

The newly approved PET radiotracer is expected to improve patient care significantly. “We have been able to reach the pinnacle of myocardial perfusion imaging with flurpiridaz," one expert said.

GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview. 

Ultrafast MCE could go on to become a go-to treatment option for obstructive coronary artery disease, according to the authors of a new first-in-human clinical study.

Trimed Popup
Trimed Popup